Cinacalcet Hydrochloride
Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | generic | 9 | SUPPLYING |
| Bryant Ranch Prepack | repackager | 4 | SUPPLYING |
| Exelan Pharmaceuticals Inc. | unknown | 3 | SUPPLYING |
| Cipla USA Inc. | generic | 3 | SUPPLYING |
| Dr.Reddy's laboratories Limited | unknown | 4 | EXITED 2026 |
Shortages, recalls, and registration changes attached to this drug concept.
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). — Recalling firm: Cipla USA, Inc. — USA Nationwide
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). — Recalling firm: Cipla USA, Inc. — USA Nationwide
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). — Recalling firm: Cipla USA, Inc. — USA Nationwide
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit — Recalling firm: Cipla USA, Inc. — Nationwide in the USA
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit — Recalling firm: Cipla USA, Inc. — Nationwide in the USA
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit — Recalling firm: Cipla USA, Inc. — Nationwide in the USA
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. — Recalling firm: Cipla USA, Inc. — Nationwide in the US
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. — Recalling firm: Cipla USA, Inc. — Nationwide in the US
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. — Recalling firm: Cipla USA, Inc. — Nationwide in the US
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit — Recalling firm: Dr. Reddy's Laboratories, Inc. — USA Nationwide.
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit — Recalling firm: Dr. Reddy's Laboratories, Inc. — USA Nationwide.
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit — Recalling firm: Dr. Reddy's Laboratories, Inc. — USA Nationwide.
